CFOR CapForce Inc.

CIK 0001293818 50 ready 8-Ks latest January 16, 2026, 6:59 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 50

Latest filing November 6, 2026, 5:08 PM ET

Top materiality 1.00

Event mix other_material ×25 · leadership ×9 · regulatory ×8

Sentiment 3 pos · 21 neg · 26 neu

Latest earnings reported 2023-Q2

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for CFOR

Highest-materiality recent filing

EIB terminates Standstill Agreement with OpGen; subsidiaries in insolvency proceedings

November 22, 2023, 6:59 PM ET other material materiality 1.00 negative item 1.02 item 9.01 ◈ Material Agreements

On Nov 20, 2023, EIB terminated the Standstill Agreement effective immediately.
Termination due to Curetis GmbH and Ares Genetics GmbH entering insolvency proceedings.

Read filing →

January 16, 2026, 6:59 PM ET M&A materiality 0.70 neutral item 1.01 item 2.01 item 9.01 ◈ M&A Transactions◈ Material Agreements

OpGen acquires iCapX for $12.3M in stock from controlling stockholder

Purchase price $12,278,703 paid via 2,028,867 shares of OpGen common stock at $6.052/share, issuance expected by Jan 20, 2026.
December 23, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 5.02 item 9.01 ◈ Equity Issuances◈ Material Agreements

OpGen extends AEI equity line to Dec 2026, cut draw size; President Lazar resigns

Supplemental letter extends equity line sale period from Dec 31, 2025 to Dec 31, 2026.
December 5, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01

OpGen appoints Christian-Laurent Bonte as CEO, replacing John Tan Honjian who remains Chairman

John Tan Honjian resigned as CEO effective Dec 1, 2025; continues as Chairman of the Board.
May 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

OpGen unit CapForce gets 2.1% equity in client for IPO advisory, forms JV for digital banking platform

CapForce assigned 2.1% equity stake and $120,000 cash from AEI Capital in client for NASDAQ direct listing advisory services.
December 27, 2024, 6:59 PM ET other material materiality 0.90 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

OpGen's Nasdaq delisting affirmed by Listing Council; trading to move to OTC Markets under OPGN

Nasdaq Listing Council upheld Panel's decision to delist OpGen for non-compliance with minimum stockholders' equity rule.
October 9, 2024, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 9.01

OpGen expands AEI Capital equity line from $3M to $9M; period extended to Dec 2025

Amendment dated Oct 3, 2024 increases maximum common stock sale to AEI Capital from $3M to $9M.
August 22, 2024, 7:59 PM ET other material materiality 0.85 negative item 1.01 item 1.02 item 3.01 item 3.02 item 9.01

OpGen receives Nasdaq delisting notice; enters $3M equity purchase agreement

Nasdaq Panel denied continued listing on Aug 16, 2024; stock suspended from trading at open on Aug 20, 2024.
August 19, 2024, 7:59 PM ET other material materiality 0.75 negative item 4.02 item 9.01

OpGen restates Q1 2024 financials due to lease indemnification accounting error

Management determined Q1 2024 unaudited financials should no longer be relied upon.
August 2, 2024, 7:59 PM ET M&A materiality 0.85 neutral item 3.02 item 5.02 item 5.01 item 9.01 ◈ executive_change ×5◈ M&A Transactions

OpGen change of control: AEI Capital acquires ~49% voting power; CEO Lazar resigns, John Tan appointed

David Lazar sold 550,000 Series E shares and rights to 2,450,000 more to AEI Capital for $2.55M.
June 11, 2024, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 item 9.01

OpGen receives Nasdaq notice for stockholders' equity deficiency; faces potential delisting

Regained bid price compliance on June 5, 2024, but same day notified of stockholders' equity deficiency (need at least $2.5M).
June 3, 2024, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 item 9.01

OpGen granted Nasdaq continued listing conditional on filing Q1 10-Q by July 8, 2024

Received Nasdaq delinquency notice for failure to file Form 10-Q for quarter ended March 31, 2024.
May 24, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 item 9.01

OpGen receives Nasdaq notice for late Q1 10-Q, adding delisting risk

Nasdaq notified OpGen on May 20, 2024 of non-compliance with Rule 5250(c)(1) due to delinquent Form 10-Q.
May 22, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.03 item 5.03 item 8.01 item 9.01

OpGen announces 1-for-10 reverse stock split to regain Nasdaq compliance; extends EIB settlement payment deadline

Reverse stock split at 1-for-10 ratio effective May 20, 2024; approved by board and stockholders on May 9, 2024.
May 14, 2024, 7:59 PM ET other material materiality 0.65 neutral item 3.03 item 5.03 item 5.07 item 9.01 ◈ Governance Changes

OpGen shareholders remove Series E conversion cap; authorize reverse split up to 1:10

Stockholders approved removal of 19.99% ownership limitation on Series E Preferred Stock, allowing conversion and voting without limit.
April 29, 2024, 7:59 PM ET other material materiality 0.70 negative item 1.01 item 8.01 item 9.01 ◈ Material Agreements

OpGen sells Unyvero customer contracts to Camtech for $218k; plans exit from Unyvero business

Sale of Unyvero customer contracts and installed base to Camtech Pte Ltd for $218,000, closing expected May 2024.
April 23, 2024, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices ×2

OpGen receives Nasdaq notice for late 10-K filing; faces delisting if not filed by June 3, 2024

Nasdaq notified OpGen on April 18, 2024 of noncompliance with Listing Rule 5250(c)(1) due to delinquent FY2023 10-K.
April 17, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 9.01

OpGen appoints David Lazar as CEO with deferred salary and concurrent CEO roles

David Lazar, age 33, appointed CEO effective April 1, 2024; also serves as Chairman of the Board.
March 29, 2024, 7:59 PM ET leadership materiality 0.90 neutral item 3.02 item 1.01 item 3.03 item 5.02 item 5.03 item 8.01 item 9.01 ◈ executive_change ×4◈ Governance Changes

OpGen: David Lazar invests $3M, takes CEO role; entire board replaced

David Lazar purchased 3M shares of Series E Preferred Stock at $1.00/share for $3M total; initial closing $200K.
February 13, 2024, 6:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

OpGen granted Nasdaq extension to June 3, 2024 for bid price compliance

Nasdaq Hearings Panel granted OpGen until June 3, 2024 to regain compliance with minimum bid price rule.
January 9, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01

OpGen raises CEO salary to $300K, signs CFO/COO consulting deals amid restructuring

CEO Oliver Schacht's base salary increased to $300,000 from $244,800 as of Jan 4, 2024.
December 12, 2023, 6:59 PM ET regulatory materiality 0.85 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

OpGen receives Nasdaq delisting notice, appeals; hearing expected Q1 2024

Nasdaq notified OpGen on Dec 6, 2023 that it is not eligible for additional bid price extension due to continued non-compliance and failure to meet initial stockholders' equity requirement.
December 5, 2023, 6:59 PM ET other material materiality 0.90 negative item 2.04 item 9.01

OpGen subsidiary Curetis defaults on ~€9.66M EIB loan; company cannot repay, warns of bankruptcy

EIB terminated standstill on Nov 20, 2023, and on Dec 4 demanded immediate repayment of ~€9.66M (principal + accrued interest) from OpGen as guarantor.
November 22, 2023, 6:59 PM ET other material materiality 1.00 negative item 1.02 item 9.01 ◈ Material Agreements

EIB terminates Standstill Agreement with OpGen; subsidiaries in insolvency proceedings

On Nov 20, 2023, EIB terminated the Standstill Agreement effective immediately.
November 14, 2023, 6:59 PM ET other material materiality 0.95 negative item 2.02 item 9.01 ◈ Earnings Releases

OpGen Q3 revenue $0.7M; subsidiaries Curetis & Ares Genetics file insolvency, going concern doubt

Total revenue Q3 2023 $0.70M vs $0.45M; nine-month $2.35M vs $1.89M.
November 7, 2023, 6:59 PM ET other material materiality 0.85 negative item 8.01 item 9.01

OpGen subsidiaries Curetis and Ares Genetics file for bankruptcy in Germany and Austria

Curetis filed bankruptcy petition with district court of Stuttgart, Germany on Nov 6, 2023.
September 7, 2023, 7:59 PM ET other material materiality 0.70 negative item 5.02 item 8.01 item 9.01

OpGen cuts exec and director salaries 40% starting Sept 1, 2023

CEO Oliver Schacht salary reduced from $408K to $244.8K; CFO Albert Weber and COO Johannes Bacher each from $300K to $180K.
August 10, 2023, 7:59 PM ET earnings materiality 0.90 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

OpGen Q2 revenue $0.7M; cash only through Sep 2023; going concern doubt

Q2 2023 revenue $0.7M vs $1.0M in Q2 2022 (prior year had one-time sale); H1 2023 revenue up 15% to $1.65M.
July 5, 2023, 7:59 PM ET debt materiality 0.75 neutral item 1.01 item 9.01 ◈ Material Agreements

OpGen subsidiary Curetis secures standstill on €3M debt due June 22, 2023

Standstill prevents EIB from exercising acceleration or termination rights on €3M principal plus interest until Nov 30, 2023 or restructuring agreement.
June 26, 2023, 7:59 PM ET debt materiality 0.60 negative item 8.01 item 9.01

OpGen subsidiary Curetis in standstill on €3M EIB loan; pays €1M to avoid default

Curetis agreed in principle to a standstill on €3M principal plus accrued interest loan tranche that matured June 22, 2023.
June 9, 2023, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

OpGen receives Nasdaq delisting notice for bid price below $1.00

On June 5, 2023, OpGen received written notice from Nasdaq that its common stock failed to maintain a minimum bid price of $1.00 per share over 30 consecutive business days.
May 4, 2023, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements ×2

OpGen closes $3.5M public offering; issues 4.5M shares/warrants, amends existing warrants

Offering included 605K shares, 3.89M pre-funded warrants, and 4.5M common warrants at $0.7785 per unit.
April 18, 2023, 7:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

OpGen files De Novo FDA request for Unyvero UTI panel; sensitivity 96.8%

Submitted De Novo classification request to FDA for Unyvero UTI panel after clinical trial.
March 30, 2023, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

OpGen reports FY2022 revenue $2.6M, down 40% YoY; guides FY2023 revenue $4-5M

FY2022 total revenue ~$2.6M vs $4.3M in 2021; Q4 revenue $722K, down 48% YoY but up 61% QoQ.

Earnings & guidance

2023-Q2 EPS reported -$2.13 filing →

Materiality & sentiment trend

Max materiality 1.00 · Median 0.65 · Most common event other_material

3 positive 21 negative 26 neutral

source · CFOR on sec.gov